Lipid-lowering therapy with the PCSK9 inhibitor evolocumab improved clinical efficacy, reducing total primary end-point events in patients with stable cardiovascular disease receiving statin therapy. The gene discussed is PCSK9; the disease is cardiovascular disorder.